CHICAGO — Fewer than 7% of patients newly diagnosed with cancer are tested for germline genetic mutations, and the percentage tested was even lower among racial and ethnic minorities, a huge study has found. Information from germline genetic testing could affect a patient’s cancer care. For example, such testing could…Read More
Related Posts
Harmony Biosciences To Acquire Zynerba Pharmaceuticals Inc
PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients…
Health News Sugar Molecule in Blood Can Predict Alzheimers Disease Study LatestLY
Washington [US], April 13 (ANI): Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies. Researchers at Sweden's Karolinska Institutet have revealed that the…
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology ASCO Annual Meeting…
LOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. AADI, a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway…
